Clinical trials: Non-Small Cell Lung Cancer (NSCLC), open to volunteers
Advanced and Metastatic NSCLC
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer
The goal of this clinical trial is to learn if diphenhydramine can improve the effectiveness and decrease the toxicity for the treatment of advanced and metastatic Non-small cell lung cancer (NSCLC) with PD1 inhibitor plus…
- Trial name
- NCT06704620
- Testing
- Diphenhydramine, Tislelizumab, Pemetrexed
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Non-small Cell Lung Cancer (NSCLC), Recurrent or Metastatic Lung Cancer
Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study
This study evaluates the efficacy and safety of Vorolanib as monotherapy for advanced non-small cell lung cancer (NSCLC) patients receiving third-line or higher treatments.
- Conditions
- Advanced Non-small Cell Lung Cancer (NSCLC), Recurrent or Metastatic Lung Cancer, Third-line and Beyond Therapy, Angiogenesis Inhibition in Oncology
- Trial name
- Vigor (NCT06728852)
- Testing
- Administration of Vorolanib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Li-kun Chen
Lung Disease, NSCLC (Non-small Cell Lung Cancer)
Cognitive Screening in Lung Cancer Patients
This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC.
- Conditions
- Lung Disease, NSCLC (Non-small Cell Lung Cancer), SCLC
- Trial name
- NCT06727370
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- European Institute of Oncology
NSCLC
Perioperative Treatment Outcomes of Early NSCLC
This is an observational study evaluating the clinical characteristics, treatment patterns, and clinical outcomes of perioperative NSCLC patients receiving different treatment strategies.
- Trial name
- Peri-R (NCT06610240)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chest Hospital
NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastasases
AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases
The goal of this observational study is to extract the imaging features of brain lesions and primary lung lesions in NSCLC patients with brain metastases by deep learning, as well as common clinicopathological parameters, which…
- Trial name
- NCT06604689
- Testing
- third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Fudan University
Solid Tumors (Phase 1), Mesothelioma
Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors
The goal of this clinical trial is to learn if drug AROG4-01 is safe in patients with solid tumors who have no available treatment alternative. Different doses will be tested in order to identify the most suitable one.
- Conditions
- Solid Tumors (Phase 1), Mesothelioma, Colorectal Carcinoma, Ovarian Cancer
- Trial name
- AROG4-01-01 (NCT06652529)
- Testing
- AROG4-01
- Volunteers
- 35 people
- Sponsor
- Aromics Therapeutics
Advanced or Metastatic NSCLC
Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
HS-10375 is an oral, highly selective, small molecular inhibitor of EGFR C797S. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10375 in Chinese advanced or metastatic NSCLC.
- Trial name
- NCT05435248
- Testing
- HS-10375
- Where
- China
- Volunteers
- 354 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lung Cancer, Nonsmall Cell, Non-Small Cell Lung Cancer NSCLC
Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy
The primary objective of this study is to assess the major pathological response (MPR) rate and pathologic complete response (pCR) rate in stage IB-IIIA non-small cell lung cancer (NSCLC) treated with a low dose of neoadjuvant…
- Trial name
- NCT06667154
- Testing
- Low-dose nivolumab combined with platinum-based doublet chemotherapy
- Where
- Brazil
- Volunteers
- 33 people
- Sponsor
- Aline Fusco Fares, MD
NSCLC, Stage I
Comparison of Sublobar and Lobectomy in Small (2 Cm or Less 0.5<CTR<1) Non-small Cell Lung Cancer: a Prospective, Multicenter Randomized Controlled Study
The early NSCLC（Non-small cell lung cancer） patients with partial solid nodules mainly composed of solid components, whose maximum tumor diameter was ≤ 2.0cm and 0.5<CTR（Consolidation tumor ratio）<1, as indicated by preoperative…
- Trial name
- NCT06028412
- Testing
- Sublobar, Lobectomy
- Where
- China
- Volunteers
- 660 people
- Sponsor
- Xiaolong Yan, Dr.
Microplastics, Lung Cancer (NSCLC)
Microplastics in the Human Respiratory System
Environmental pollution from plastics has become a significant global issue, with microplastics-tiny particles resulting from plastic degradation-being increasingly detected in various environments, including aquatic ecosystems…
- Conditions
- Microplastics, Lung Cancer (NSCLC), Lung Transplantation
- Trial name
- NCT06603675
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Wielkopolskie Centrum Pulmonologii i Torakochirurgii
NSCLC, Stage IIIA, NSCLC (non-small Cell Lung Cancer)
Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer
To investigate the efficacy and safety of neoadjuvant treatment with Tislelizumab combined with chemotherapy for initially unresectable N2/III non-small cell lung cancer.
- Trial name
- NCT06614231
- Testing
- Tislelizumab Combined With Chemotherapy
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Lung Cancer (NSCLC)
A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC
Evaluate the efficacy and safety of neoadjuvant furmonertinib combined with anlotinib and chemotherapy in patients with resectable stage II-III EGFR mutation-positive non-small cell lung cancer.
- Trial name
- NCT06585644
- Testing
- Furmonertinib in combination with Anrotinib and chemotherapy
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV
Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
The goal of this clinical trial is to learn if Stereotactic Body Radiotherapy (SBRT) can treat the oligo-progressive metastatic non-small cell lung cancer (NSCLC) after first-line chemotherapy.
- Conditions
- Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV, OligoProgressive Metastatic Disease
- Trial name
- OPPRESS (NCT06523673)
- Testing
- Stereotactic Body Radiotherapy, second-line systemic therapy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
NSCLC Stage IV, Brain Metastases
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer, has a significant risk of brain metastasis (BM). Historically, the median overall survival for advanced NSCLC patients with BM was under six months with…
- Trial name
- NCT06501391
- Testing
- PD-L1/PD-1 inhibitor and chemotherapy, SRT or WBRT
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Fudan University
Non-Small Cell Lung Cancer NSCLC
Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)
It is a single-center, open-labeled, single-arm, non-randomized investigator-initiated trial evaluating the efficacy and safety of anti-Trop2 U-CAR-NK Cells Therapy combined with Chemotherapy for Relapsed/Refractory Non-Small…
- Trial name
- NCT06454890
- Testing
- Anti-Trop2 CAR-NK cell
- Volunteers
- 50 people
- Sponsor
- Henan Cancer Hospital
Gastric Cancer, Esophageal Cancer
a Single-arm, Single-center, Open Clinical Study
This trial plans to enroll many patients with advanced solid tumors to complete GK01 cell transfusion, including but not limited to advanced gastric cancer, esophageal cancer, cervical cancer, triple-negative breast cancer, and…
- Conditions
- Gastric Cancer, Esophageal Cancer, Cervical Cancer, Non-Small Cell Lung Cancer NSCLC
- Trial name
- GK-01 (NCT06431100)
- Testing
- TCR T-cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Geekgene Technology Co., LTD
NSCLC Stage II, NSCLC, Stage IIIA
Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC
Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA and select IIIB (T3N2 only) non-squamous Non-Small Cell Lung Cancer (NSCLC) to…
- Conditions
- NSCLC Stage II, NSCLC, Stage IIIA, NSCLC Stage IIIB
- Trial name
- iReP (NCT04865250)
- Testing
- Atezolizumab 1200 mg abs day 1 q22 (iv)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Heidelberg
Non-Small Cell Lung Cancer NSCLC
Clinical Study of 18F-Alfatide Injection PET/CT
This is a multicenter, open, non-inferiority Phase III clinical study to evaluate the efficacy of 18F-Alfatide Injection PET/CT compared with 18F-FDG PET/CT in the diagnosis of lymph node metastasis in non-small cell lung cancer.
- Trial name
- NCT06416852
- Testing
- 18F-Alfatide Injection, 18F-FDG Injection
- Where
- China
- Volunteers
- 428 people
- Sponsor
- Yantai LNC Biotechnology Singapore PTE. LTD.
NSCLC, Stage III, Locally Advanced Lung Carcinoma
Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients
This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer participants who will receive durvalumab can predict treatment toxicity.
- Trial name
- Microdurva (NCT04680377)
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Jun Zhang, MD, PhD
Lung Cancer, NSCLC Stage IV
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzumab).
- Conditions
- Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC
- Trial name
- Cabatezo-1 (NCT05859217)
- Testing
- Cabozantinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jun Zhang, MD, PhD